Research Interests

My laboratory is interested in innovative anticancer agents, targeted cancer therapy, the mechanisms of action of and/or resistance to anticancer agents, and molecular signatures or biomarkers for predicting treatment response or early diagnosis of lung cancers. Current study includes TRAIL-armed oncolyticadenovirotherapy, small molecules targeted to K-Ras and the C-terminal domain of RNA polymerase II, biomarkers in primary lung cancer, and molecular signatures of response to targeted therapy in lung cancer. Our long term goal is to develop pathway-targeted therapeutic agents that are minimally toxic and highly effective to treat refractory tumors and identify molecular signatures for predicting response or early diagnosis.